HeartBeam Inc. (BEAT)

NasdaqCM: BEAT · Real-Time Price · USD

0.47

-0.02 (-4.08%)

At close: Aug 28, 2026, 2:56 PM

0.47

+0.00%

After-hours: 4:10 PM

The price, the headline numbers and the latest news, in one place.

-4.08% (1D)

Bid	0.34
Market Cap	26.31M
Revenue (ttm)	n/a
Net Income (ttm)	-20.3M
	-0.79
	-0.51
	n/a
	-0.88
P/B (ttm)	3.22
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

Ask	0.48
Volume	374,478
Avg. Volume (20D)	723,084
Open	0.48
Previous Close	0.49
Day's Range	0.46 - 0.49
52-Week Range	0.46 - 4.00
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About BEAT

HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment ...

[Read more]

Industry Health Information Services

Sector Healthcare

IPO Date Nov 11, 2021

Employees 16

Stock Exchange NasdaqCM

Ticker Symbol BEAT

Website https://www.heartbeam.com

Full Company Profile

Financial Performance

In 2025, HeartBeam's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -21.02M, an increase of 8.06%.

Financial Statements

Earnings Surprise

HeartBeam has released their quarterly earnings on Aug 13, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.1 misses estimates by -0.01, with 33.33% YoY growth.

Next Earnings Release

HeartBeam Inc. is scheduled to release its earnings on Nov 12, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

2 weeks ago · Moby

HeartBeam, Inc. Q2 2026 Earnings Call Summary

Moby summary of HeartBeam, Inc.'s Q2 2026 earnings call

2 weeks ago · GuruFocus.com

HeartBeam Inc (BEAT) (Q2 2026) Earnings Call Highlights: FDA Submission Advances and Commercial ...

HeartBeam Inc (BEAT) progresses its regulatory pathway with a 510(k) pre-submission while expanding commercial agreements and extending its cash runway into 2027.

2 months ago · Simply Wall St.

HeartBeam (BEAT) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Slower Ramp

HeartBeam’s latest analyst update centers on a reduced fair value estimate, with the central value per share moving from about US$5.08 to US$3.83. Research commentary links these cuts to tempered expe...